On December 15, 2025, Mr. Lan, the Party Secretary of Nanjing Medical University, and Mr. Li, Chairman of Suzhou Yuanju Pharmaceutical, along with a delegation of over ten individuals, visited Jiudian Pharmaceutical to witness the official signing of the innovation drug project transfer agreement between Jiudian Pharmaceutical and Yuanju Pharmaceutical. According to the agreement, Jiudian Pharmaceutical will acquire global ownership and intellectual property rights of the small molecule pain relief innovation drug YJ2301 for a total amount not exceeding 400 million yuan.

Chronic pain is a major health issue affecting the quality of life of hundreds of millions of people worldwide. In China, the population of chronic pain patients is vast, yet current treatment methods still face significant unmet clinical needs in terms of efficacy, safety, and long-term management of patient medications.

The YJ2301 project is an innovative drug for neuropathic pain designed based on a novel mechanism of action. Preclinical research data indicates that the drug has outstanding analgesic effects and is expected to address the limitations of existing medications, such as limited efficacy, poor safety (e.g., sedation, drowsiness, and addiction), and the risk of drug resistance with long-term use. The drug is set to provide a new solution for the treatment of neuropathic pain, with a broad market prospect.

Pain management is a key area of expertise for Jiudian Pharmaceutical, which currently holds nearly 30 approved products in this category, including eight topical formulations. Representative products, such as Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Compound Methyl Salicylate Gel Patch, Lidocaine Gel Patch, Warm Moxa-Substitute Plaster, and Lumbar & Bone Tonic Plaster, are all leading products in the domestic and international pain relief field.

The company’s new drug development in the pain field has always been a top priority in its R&D system. Over ten products, including the innovative Chinese medicine pain relief gel patch, are in the review stage or under development, with two innovative drugs already in clinical stages. Meanwhile, several other targets are under investigation. Mr. Yang, General Manager of Jiudian Pharmaceutical, stated at the signing ceremony that the inclusion of the YJ2301 project will further enrich the company’s pain relief product portfolio. By leveraging the full-category strategy of "Traditional Chinese Medicine + Chemical Drugs" and "Topical + Oral" formulations, Jiudian has built a comprehensive product cluster that covers all pain management scenarios and aims to offer a complete solution for pain patients.

Prior to the signing, Jiudian Pharmaceutical launched a brand upgrade event where it introduced the brand slogan "Pain Relief Plaster, Choose Jiudian" and unveiled the "Jiudian Pain Relief Master" super symbol, along with a series of new packaging for pain relief products. This strategic move aims to strengthen Jiudian's brand image as a "Pain Relief Patch Expert" and marks the shift from a "product-only" strategy to a "product and brand" dual-core drive for its strategic transformation. This transformation aims to further solidify the company’s competitive edge in the pain relief sector.

As a significant technical introduction project under Jiudian Pharmaceutical’s strategy of focusing on innovative drug development, the signing of this agreement marks a key step in the company’s innovative drug layout in the pain field. By proactively entering the pain relief innovation drug track, Jiudian Pharmaceutical is steadily transforming from a traditional generic drug manufacturer into an innovation-driven pharmaceutical company, injecting new momentum into its long-term sustainable development. Looking ahead, the company is expected to continue building a diversified portfolio of innovative products through independent R&D and strategic collaborations, positioning itself favorably in the intense market competition.